These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 29103159)

  • 1. Model-based optimization of G-CSF treatment during cytotoxic chemotherapy.
    Schirm S; Engel C; Loibl S; Loeffler M; Scholz M
    J Cancer Res Clin Oncol; 2018 Feb; 144(2):343-358. PubMed ID: 29103159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group.
    Tesch H; Diehl V; Lathan B; Hasenclever D; Sieber M; Rüffer U; Engert A; Franklin J; Pfreundschuh M; Schalk KP; Schwieder G; Wulf G; Dölken G; Worst P; Koch P; Schmitz N; Bruntsch U; Tirier C; Müller U; Loeffler M
    Blood; 1998 Dec; 92(12):4560-7. PubMed ID: 9845521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group (GHSG).
    Engel C; Loeffler M; Schmitz S; Tesch H; Diehl V
    Ann Oncol; 2000 Sep; 11(9):1105-14. PubMed ID: 11061603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
    Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
    J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma.
    Grigg A; Solal-Celigny P; Hoskin P; Taylor K; McMillan A; Forstpointner R; Bacon P; Renwick J; Hiddemann W;
    Leuk Lymphoma; 2003 Sep; 44(9):1503-8. PubMed ID: 14565651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and -dynamic modelling of G-CSF derivatives in humans.
    Scholz M; Schirm S; Wetzler M; Engel C; Loeffler M
    Theor Biol Med Model; 2012 Jul; 9():32. PubMed ID: 22846180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Granulocyte colony-stimulating factor (G-CSF) prevents dose-limiting neutropenia in lymphoma patients receiving standard dose chemotherapy.
    Dotti G; Stella CC; Mangoni L; Cottafavi L; Caramatti C; Almici C; Rizzoli V
    Haematologica; 1995; 80(2):142-5. PubMed ID: 7543069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is escalated BEACOPP a standard therapy for advanced Hodgkin's disease?
    Carde P; Cavalli F; Diehl V; Franklin J
    Hematol J; 2000; 1(4):282-90. PubMed ID: 11920203
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States.
    Lyman G; Lalla A; Barron R; Dubois RW
    Curr Med Res Opin; 2009 Feb; 25(2):401-11. PubMed ID: 19192985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of granulocyte colony-stimulating factor (filgrastim) in maintaining dose intensity during conventional-dose chemotherapy with ABVD in Hodgkin's disease.
    Silvestri F; Fanin R; Velisig M; Barillari G; Virgolini L; Zaja F; Russo D; Baccarani M
    Tumori; 1994 Dec; 80(6):453-8. PubMed ID: 7534963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biweekly COP-BLAM (cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin and procarbazine) regimen combined with granulocyte colony stimulating factor (G-CSF) for intermediate-grade non-Hodgkin's lymphoma.
    Niitsu N; Umeda M
    Eur J Haematol; 1996 Mar; 56(3):163-7. PubMed ID: 8598236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of pegfilgrastim primary prophylaxis and risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or non-Hodgkin's lymphoma.
    Langeberg WJ; Siozon CC; Page JH; Morrow PK; Chia VM
    Support Care Cancer; 2014 Aug; 22(8):2167-75. PubMed ID: 24652049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
    Eichenauer DA; Plütschow A; Kreissl S; Sökler M; Hellmuth JC; Meissner J; Mathas S; Topp MS; Behringer K; Klapper W; Kuhnert G; Dietlein M; Kobe C; Fuchs M; Diehl V; Engert A; Borchmann P
    Lancet Oncol; 2017 Dec; 18(12):1680-1687. PubMed ID: 29133014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized multicentre trial of filgrastim as an adjunct to combination chemotherapy for Hodgkin's disease. West of Scotland Lymphoma Group.
    Dunlop DJ; Eatock MM; Paul J; Anderson S; Reed NS; Soukop M; Lucie N; Fitzsimmons EJ; Tansey P; Steward WP
    Clin Oncol (R Coll Radiol); 1998; 10(2):107-14. PubMed ID: 9610900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spermatogenesis in Hodgkin's lymphoma patients: a retrospective study of semen quality before and after different chemotherapy regimens.
    Paoli D; Rizzo F; Fiore G; Pallotti F; Pulsoni A; Annechini G; Lombardo F; Lenzi A; Gandini L
    Hum Reprod; 2016 Feb; 31(2):263-72. PubMed ID: 26705149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
    Wunderlich A; Kloess M; Reiser M; Rudolph C; Truemper L; Bittner S; Schmalenberg H; Schmits R; Pfreundschuh M; Loeffler M;
    Ann Oncol; 2003 Jun; 14(6):881-93. PubMed ID: 12796026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary prophylaxis with pegfilgrastim during the first cycle of R-CHOP to avoid reduction of dose intensity in elderly patients.
    Ise M; Matsuda K; Shimura A; Masamoto Y; Kurokawa M
    Int J Hematol; 2021 Jun; 113(6):823-831. PubMed ID: 33738702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma.
    Blayney DW; McGuire BW; Cruickshank SE; Johnson DH
    Oncologist; 2005 Feb; 10(2):138-49. PubMed ID: 15709216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treating Hodgkin's disease: for whom the more means better?].
    Illés A
    Magy Onkol; 2004; 48(2):157-61. PubMed ID: 15351812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of chemotherapy-induced neutropenia using G-CSF with VACOP-B--a case report.
    Anglin P; Strauss BA; Brandwein JM
    Leuk Lymphoma; 1993 Nov; 11(5-6):469-72. PubMed ID: 7510192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.